Comparison of the Neuromuscular Blocking Effect of Atracurium and Vecuronium on the Adductor Pollicis and the Geniohyoid Muscle in Humans

Background: Residual paralysis of suprahyoid muscles may occur when the adductor pollicis response has completely recovered after the administration of a neuromuscular blocking agent. The response of the geniohyoid muscle to intubating doses of muscle relaxants is evaluated and compared to that of adductor pollicis.

Methods: Sixteen patients undergoing elective surgery under general anesthesia were given 5-7 mg *symbol* kg sup -1 thiopental and 2 micro gram *symbol* kg sup -1 fentanyl intravenously for induction of anesthesia. Eight (half) patients then received 0.5 mg *symbol* kg sup -1 atracurium, and the other eight received 0.1 mg *symbol* kg sup -1 vecuronium. The evoked response (twitch height, TH) of the adductor pollicis was monitored by measuring the integrated electromyographic response (AP EMG) on one limb and the mechanical response, using a force transducer (AP force), on the other. The activity of geniohyoid muscle (GH EMG) was measured using submental percutaneous electrodes. The following variables were measured: maximal TH depression; onset time for neuromuscular blockade to 50%, 90%, and maximal TH depression (OT50, OT90, and OTmax); times between administration of neuromuscular blocking agent and TH recovery to 10%, 25%, 50%, 75%, and 90% of control; and time for return of train-of-four ratio to return to 0.7.

Results: The principal findings were (1) OTmax was significantly (P < 0.01) shorter for geniohyoid than for adductor pollicis after either atracurium or vecuronium (OTmax was 216, 256, and 175 s for AP force, AP EMG, and GH EMG, with atracurium and 181, 199, and 144 s with vecuronium, respectively), and (2) the evoked EMG of geniohyoid recovered at the same speed as the EMG of adductor pollicis after an intubating dose of atracurium or vecuronium (recovery of TH to 75% of control at 50, 48, 42 min with AP force, AP EMG, and GH EMG with atracurium and 46, 45, and 42 min with vecuronium, respectively).     

Monitoring orbicularis oculi predicts good intubating conditions after vecuronium in children

Purpose

The aim of the study was to compare visual estimation of onset of neuromuscular blockade at both the adductor pollicis (AP) and the orbicularis oculi (OO) in children and to determine if monitonng the OO could predict good intubating conditions during vecuronium-induced neuromuscular blockade.

Methods

Thirty ASA I–II children (1.5–9 yr) were studied. Anaesthesia was induced with 6–8 mg · kg^?1 thiopentone. The ulnar nerve at the wrist and the temporal branch of the facial nerve were stimulated every 10 sec using train of-four (TOF) stimuli. Vecuronium. 0.15 mg · kg, was administered as a bolus. The responses at both the OO and the AP were evaluated visually. Patients were randomly divided into two groups. In the AP group (n = 15), the trachea was intubated when the AP was completely blocked. In the OO group (n = 15), intubation was performed when the OO was completely blocked. Intubating conditions were scored on a scale of 1 to 4.

Results

All the patients had complete blockade at both the orbicularis oculi and the adductor pollicis. In the two groups, time from injection of vecuronium to complete neuromuscular blockade was shorter at the orbicularis oculi than at the adductor pollicis, 1.5 ± 0.5 min vs 2.3 ± 0.7 min, respectively, (P < 0.05; mean ± SD) in the AP group, 1.7 ± 0.3 min vs 2.3 ± 0.8 min, respectively, in the OO group (P < 0.05). Intubating conditions were excellent in all patients except one. where it was rated as good. They did not differ between groups.

Conclusion

Following administration of 0.15 mg · kg^?1 vecuronium in children, monitoring of the OO can detect good intubating conditions 0.7 min earlier than with monitoring of the AP.     

Facilitation of rapid-sequence intubation with large-dose vecuronium with or without priming.

STUDY OBJECTIVES: To determine the effect of priming on the intubation and onset times of vecuronium 0.3 mg/kg. DESIGN: Randomized, unblinded study. SETTING: Operating rooms and postanesthetic recovery unit of a university-affiliated general hospital. PATIENTS: Thirty female ASA physical status I and II patients scheduled for intraperitoneal surgery divided into two groups of 15 each. INTERVENTIONS: Anesthesia was induced and maintained with sufentanil, droperidol, thiopental sodium, and nitrous oxide in oxygen. Patients in Group 1 were given vecuronium 0.015 mg/kg 4 minutes before induction and vecuronium 0.285 mg/kg 1 minute after induction. Patients in Group 2 received a single 0.3 mg/kg dose of vecuronium 1 minute after thiopental sodium. The ulnar nerve was stimulated every 10 seconds with train-of-four supramaximal impulses of 0.2 millisecond duration at 2 Hz. The compound electromyogram (EMG) of the adductor pollicis was continuously recorded. The trachea was intubated when the amplitude of the EMG decreased to 15% to 25% of control. At the end of surgery, residual neuromuscular block was reversed with edrophonium 0.75 mg/kg. MEASUREMENTS AND MAIN RESULTS: All patients in Group 1 could be intubated in 80 seconds or less, and the longest onset time was 120 seconds. In Group 2, the longest intubation time was 140 seconds, and the longest onset time was 200 seconds. Clinical durations in both groups were unpredictable, ranging from 47 to 185 minutes in Group 1 and from 63 to 160 minutes in Group 2. Ten of the 30 patients required an additional 0.5 mg/kg of edrophonium for antagonism of the residual neuromuscular block. There were no significant changes in heart rate or blood pressure attributable to vecuronium. CONCLUSIONS: Seventy-five percent to 85% neuromuscular block of the adductor pollicis, required for atraumatic tracheal intubation, developed in 80 seconds or less when vecuronium 0.3 mg/kg was administered in divided doses and in 140 seconds or less when it was injected as a single bolus dose. Clinical duration of vecuronium 0.3 mg/kg is long and unpredictable, and reversal of residual neuromuscular block may require larger doses of anticholinesterases. It is recommended that an intubating dose of vecuronium 0.3 mg/kg be used only in patients undergoing long surgical procedures that require prolonged postanesthetic mechanical ventilation.     

Rapid tracheal intubation with atracurium - a comparison of priming intervals

determine the optimal interval between the administration of the priming dose and the intubating dose, atracurium was given to 44 patients either in a single dose of 0.5 mg.kg^-1 or in an initial dose of0.06mg.kg^-1 followed two, three or five minutes later with 0.44 mg.kg^-1. When atracurium was given as a single bolus of 0.5 mg. kg^-1 the time to 100 per cent twitch suppression (onset time) was90.9 ± 36 (mean ± SD) seconds. When the priming interval was two minutes, the onset time of the intubating dose was 76.6 ± 42.2 seconds (p = NS). But when the priming interval was three or five minutes, the onset timeswere42.2 ± 16.5(p<0.01)and52.6 ± 28.8(p < 0.05) seconds respectively. Waiting for five minutes after the administration of the priming dose did not improve the intubating conditions. It is concluded that three minutes appears to be the optimal time interval for the administration of atracurium in divided doses. When a priming dose of atracurium is given three minutes before the intubating dose, it can provide an alternative to succinylcholine for rapid endotracheal intubation.     

Efficacy of different doses of atracurium on intubating conditions of burned patients

BackgroundBurned patients exhibit resistant response to nondepolarizing muscle relaxants. This study was designed to investigate the efficacy of high dose atracurium (3 and 4 times ED95) with and without application of the priming principle on the intubating conditions and the onset times in burned patients.MethodsASA physical status I and II patients undergoing burn related surgery, were randomly allocated into one of four groups of 20 patients each. Group I received 1 ml placebo followed 3 min later by atracurium 0.75 mg/kg, group II received atracurium 0.04 mg/kg as the priming dose followed 3 min later by atracurium 0.71 mg/kg, group III received 1 ml placebo followed 3 min later by atracurium 1 mg/kg and group IV received atracurium 0.04 mg/kg as the priming dose followed 3 min later by atracurium 0.96 mg/kg. Datex relaxograph was used at the adductor pollicis to monitor and record the twitch response to the train of four (TOF) stimulation.ResultsThe conditions for intubation improved significantly with increasing the dose of atracurium, as we seen, when comparing patients in group IV and group I. Onset times were significantly delayed in groups I and II compared with groups III and IV.ConclusionCombinations of 4 times ED95 of atracurium together with the application of the priming principle are required to overcome the resistance and produce satisfactory intubating conditions in burned patients.     

Rapid-sequence orotracheal intubation: a comparison of three techniques

The authors compared tracheal intubating conditions using three techniques for rapid-sequence orotracheal intubation. Sixty patients were randomly assigned to one of three groups: priming with vecuronium (0.01 mg/kg priming dose, 4-min priming interval, 0.14-mg/kg intubating dose along with thiopental 4-6 mg iv); timing with vecuronium (0.15-mg/kg intubating dose given before thiopental and timed to weakness of hand grip); and succinylcholine (1.5 mg/kg). Blinded intubators graded intubating conditions 60 s after the induction of anesthesia with thiopental. Intubation scores in the succinylcholine group were significantly better than in the priming group (P = 0.009). Intubation scores of the succinylcholine and the timing groups were not significantly different. Use of the timing principle for rapid-sequence orotracheal intubation is a reliable alternative in cases where succinylcholine is contraindicated.     

Potency of atracurium on masseter and adductor pollicis muscles in children

The sensitivity of the masseter to atracurium was measured in ten children aged 3–10 yr undergoing elective surgery, and compared with that of the adductor pollicis. During nitrous oxide-halothane anaesthesia and mechanical ventilation, supramaximal nerve stimulation was applied to the ulnar nerve at the elbow and to the nerve to the masseter, at a point inferior to the zygomatic arch, anterior to the mandibular condyle. Jaw closure was measured by a force displacement transducer system attached to an oral airway and connected to a metal frame fixed to the operating table 10 cm caudad to the chin. Cumulative dose—response curves for atracurium were obtained by the injection of doses followed by an infusion to compensate for elimination. The mean ED_5Os and ED₉₅s were similar at the masseter and the adductor pollicis. At the masseter, these were 0.150 ±0.013, mean ±SEM, mg · kg^?1 and 0.254 ±0.021 mg · kg^?1, respectively. At the adductor pollicis, corresponding values were 0.145 ±0.009 mg · kg^?1, and 0.259 ±0.016 mg · kg^?1. However, this relationship was not constant in every patient, and in some patients the masseter was much more sensitive than the adductor pollicis. The time from injection of the first dose of atracurium to maximum blockade was 2.5 ±0.2 min at the masseter and 3.2 ±0.2 min at the adductor pollicis (P < 0.05). It is concluded that when atracurium is administered to paediatric patients, neuromuscular blockade is usually of the same intensity at each muscle but occurs sooner at the masseter than at the adductor pollicis. However, because of the large interpatient variability, return of adductor pollicis function may not imply complete masseter muscle recovery.     

Comparison of duration of neuromuscular blocking effect of atracurium and vecuronium in young and elderly patients

In a controlled, randomized study, we evaluated duration ofneuromuscular block in 80 patients undergoing routine abdominalsurgery. Forty patients were aged 18–50 yr (control group)and 40 patients were more than 65 yr (elderly group). All patientshad normal plasma creatinine concentrations. After inductionof anaesthesia, patients were allocated randomly to receiveeither atracurium 0.5 mg kg^–1 or vecuronium 0.1 mg kg^–1to facilitate tracheal intubation. Monitoring of the evokedresponse of the adductor pollicis muscle to supramaximal singletwitch ulnar nerve stimulation every 10 s was performed andmeasured with a strain gauge. Repeat doses of atracurium 0.1mg kg^–1 or vecuronium 0.02 mg kg^–1 were administeredwhen the adductor pollicis response recovered to 25% of thecontrol twitch height. We found that the duration of actionof the initial dose of atracurium was similar in the controland elderly groups, and it did not vary after repeated doses.However, the initial dose of vecuronium caused a significantlylonger period of clinical block in the elderly group comparedwith the controls, and the duration of action of repeated doseswas longer in the elderly group. We conclude that as there isa risk of prolonged effect of vecuronium in the elderly, monitoringof neuromuscular function is recommended in this group. Alternatively,atracurium should be preferred for prolonged surgery in elderlypatients.     

Priming with atracurium: improving intubating conditions with additional doses of thiopental

The effects of different intubating doses of atracurium on the time of onset, and the effect of an additional dose of thiopental on intubating conditions, were studied in 72 patients divided into six groups (n = 12 in each). Stratified sampling was used to obtain an even sex distribution. Groups I, III, and V (controls) received atracurium as a single bolus dose of 0.4, 0.5 or 0.6 mg/kg respectively. Groups II, IV, and VI received an initial (priming) dose of 0.05 mg/kg followed 3 min later by 0.35, 0.45, or 0.55 mg/kg respectively. The time of onset, that is the time from the intubating dose to complete suppression of the train-of-four (TOF) response, was significantly accelerated after administration of atracurium in divided doses. Increasing the intubating dose of atracurium after an initial 0.05 mg/kg from 0.35 to 0.55 mg/kg did not result in further significant acceleration of the onset time, but resulted in prolongation of the duration of neuromuscular blockade. When divided doses of atracurium were given, administration of 2 mg/kg thiopental (in addition to the 5 mg/kg used for induction) before the injection of the intubating dose resulted in improvement of intubating conditions as reflected by statistically significant changes in intubating scores. This result was probably due to the increase by thiopental in the depth of anesthesia. Therefore, when thiopental is given as supplement, the priming technique can be made to provide better conditions for tracheal intubation in less than 90 sec.     

Priming with vecuronium and atracurium--a comparison

Vecuronium (V) and atracurium (A) were compared in a randomised study in premedicated patients undergoing laparoscopy for gynecological pathology. Both groups contained ten patients. Anesthesia was induced with fentanyl (0.1 mg) and thiopentone (1 mg/kg initially and subsequently 4 mg/kg). A priming dose of vecuronium (20 micrograms/kg) or atracurium (100 micrograms/kg) was given one minute before the intubating dose (60 micrograms/kg for vecuronium and 300 micrograms/kg for atracurium). Ninety seconds thereafter intubation was performed. Maintenance of anesthesia consisted of isoflurane at an inspiratory concentration of 1% in a mixture of O2/N2O (50%/50%) with small supplements of fentanyl. Neuromuscular block was monitored with the Datex Relaxograph. Results show that neither drug offers major clinical advantages over the other: there is no difference in speed of onset (V:T190sec 14.6 +/- 4.3%; A:T190sec 23.5 +/- 6.5%; Mean +/- SEM) and duration of neuromuscular block (V:T150sec 34.2 +/- 3.5 min; A:T150sec 41.3 +/- 2.8 min; Mean +/- SEM) and intubation conditions are almost identical.     

Intubationsbedingungen und Verlauf der neuromuskulären Blockade nach Rocuronium bei endoskopischen Operationen in der HNO-Heilkunde

Rocuronium is a new nondepolarizing muscle relaxant for which a fast onset has been described. The goal of this study was to examine whether the characteristics of rocuronium could make it an appropriate relaxant for the anaesthetic management of operations of intermediate duration such as endoscopic upper airway surgery. These operations, which require the anaesthesiologist and surgeon to ”share” the patient’s airway, require good muscle relaxation for endotracheal intubation and placement of endoscopic instruments. In addition, the time course of neuromuscular blockade and its relation to the quality of intubating conditions were analysed. Methods: The study was approved by the local ethics committee; 30 patients (ASA status 1–3) scheduled for elective endoscopic upper airway surgery were included after written informed consent. Exclusion criteria were suspected difficult intubating conditions, neuromuscular disease, or antibiotic therapy with aminoglycosides during the last 24?h. Anaesthesia was induced by propofol 2?mg/kg and alfentanil 1?mg after volume loading with 500?ml Ringer’s lactate and preoxygenation, and was maintained by propofol infusion 5–8?mg/kg/h and repetitive alfentanil injections according to clinical needs. Endotracheal intubation was performed by a senior anaesthesiologist 90?s after injection of rocuronium 0.6?mg/kg (2×ED₉₅). Intubating conditions were graded 1 to 4 (1=excellent, 2=good, 3=sufficient, 4=inadequate). Acceleromyography was used for neuromuscular monitoring by means of the TOF-guard (Organon Teknika/Biometer). The adduction movement of the thumb was measured by an acceleration transducer while stimulating the ulnar nerve at the wrist via surface electrodes in a supramaximal train-of-four (TOF) mode (2?Hz every 15?s). Twitch height and TOF ratio were documented during the course of neuromuscular blockade. Data are presented as mean±standard deviation. Results: Patients were aged 37 to 64 years (mean 54±7). Intubating conditions were excellent in 17 cases and good in 7. In 2 cases intubating conditions were graded sufficient, as patients could be easily intubated but showed clear diaphragmatic movements at intubation. In 4 patients intubating conditions could not be judged, as a laryngoscopic view of the glottic structures was impossible for anatomic reasons. Neuromuscular block at intubation was 78±22%, onset time 152±62?s, clinical duration 30±8?min, and recovery index 11±4?min. The TOF ratio required 51±14?min to return to 0.7. Conclusions: Good to excellent intubating conditions can be expected 90?s after injection of rocuronium 0.6?mg/kg. Diaphragmatic reactions cannot be excluded. Complete relaxation of the adductor pollicis muscle is not necessary for endotracheal intubation. Intubation at a certain time interval, for example, 90?s after injection of rocuronium 0.6?mg/kg, can be recommended. Onset and recovery characteristics of rocuronium make it an appropriate relaxant for the anaesthetic management of operations of intermediate duration such as endoscopic upper airway surgery. Care should be given, however, to detect inadequate recovery of neuromuscular transmission, as there are considerable interindividual differences in recovery.     

Comparison of intubating conditions with atracurium, vecuronium and pancuronium

A blind trial, comparing time of onset of satisfactory conditions for tracheal intubation with atracurium 0.6 mg/kg, vecuronium 0.1 mg/kg and pancuronium 0.1 mg/kg is described. Intubation was attempted at 30-second intervals in 60 patients, randomly allocated to receive one of the above muscle relaxants. Patients receiving atracurium 0.6 mg/kg could be intubated from 30 to 120 seconds. Patients receiving either vecuronium 0.1 mg/kg or pancuronium 0.1 mg/kg were able to be intubated between 60 and 240 seconds. The results showed a statistically significant earlier onset of satisfactory intubating conditions with atracurium than with vecuronium or pancuronium in these doses but no difference between vecuronium and pancuronium.     

Visual estimation of onset time at the orbicularis oculi after five muscle relaxants: application to clinical monitoring of tracheal intubation.

The onset time of neuromuscular blockade at the adductor pollicis (AP) is different among neuromuscular blocking drugs, but these discrepancies had never been studied at the orbicularis oculi (OO). The purpose of this study was to verify if the differences in onset time observed at the AP still existed at the OO and to score the intubating conditions using monitoring at the OO after five muscle relaxants. The study included 172 adults aged 18-75 yr. Anesthesia was induced with fentanyl and propofol. Atracurium (0.5 mg/kg), mivacurium (0.20 mg/kg), rocuronium (0.6 mg/kg), succinylcholine (1.0 mg/kg), or vecuronium (0.08 mg/kg) was injected by random allocation. Time to complete disappearance of the response at the OO was assessed visually after train-of-four stimulation of the facial nerve. Laryngoscopy was then performed, and intubating conditions were determined on a scale of 1-4. Results were based on 150 patients. Onset time at the OO was (mean +/- SD): succinylcholine (57 +/- 17 s) < mivacurium (99 +/-19 s) = rocuronium (99 +/- 47 s) < atracurium (129 +/-33 s) = vecuronium (135 +/- 38 s) (P < 0.05). Overall intubating conditions were excellent (84%), good (14%), poor (1.3%), impossible (0.7%), and were similar among the five groups. We conclude that differences in onset time of muscle relaxants observed at the AP were also found at the OO. Visual estimation of the response at the OO correctly predicted good-to-excellent intubating conditions in more than 90% of cases for all the currently available muscle relaxants. IMPLICATIONS: Onset time of neuromuscular blockade, as estimated visually at the orbicularis oculi, depends on the muscle relaxants given. Regardless of the relaxant used, intubating conditions at loss of orbicularis oculi are acceptable.     

Monitoring of vecuronium-induced neuromuscular block at the sternocleidomastoid muscle in anesthetized patients

Purpose

To assess the degree of neuromuscular block acceleromyographically at the sternocleidomastoid muscle.

Methods

Eighteen adult patients scheduled for air–oxygen–sevoflurane–fentanyl and epidural anesthesia were studied. In the patients, the right accessory nerve and the sternocleidomastoid muscle were stimulated and the contraction of the sternocleidomastoid muscle was evaluated acceleromyographically. Simultaneously, the response of the adductor pollicis muscle was measured electromyographically. Supramaximal stimulating current, degree of maximum neuromuscular block after vecuronium 0.1 mg/kg, and onset of or recovery from vecuronium-induced neuromuscular block were compared between the two muscles.

Results

The supramaximal stimulating current at the sternocleidomastoid muscle was significantly higher than that at the adductor pollicis muscle (54.8 ± 7.1 vs. 33.7 ± 10.3 mA, mean ± SD, P < 0.001). The onset of neuromuscular block at the sternocleidomastoid muscle did not significantly differ from that at the adductor pollicis muscle (214 ± 117 vs. 161 ± 87 s, P = 0.131). The degree of maximum neuromuscular block at the sternocleidomastoid muscle was significantly less than that at the adductor pollicis muscle (93.6 ± 3.1 vs. 99.2 ± 2.5%, P < 0.001). During recovery from neuromuscular block, T1/control and train-of-four ratio measured at the sternocleidomastoid muscle were significantly higher than those at the adductor pollicis muscle 10–30 and 40–120 min after vecuronium, respectively (P < 0.05).

Conclusion

The sternocleidomastoid muscle is more resistant to vecuronium than the adductor pollicis muscle. Recovery from neuromuscular block is faster at the sternocleidomastoid muscle than at the adductor pollicis muscle.     

Benzodiazepines and neuromuscular blocking drugs in patients

The interaction between four benzodiazepines (diazepam, lorazepam, lormetazepam and midazolam) and two nondepolarizing neuromuscular blocking drugs (vecuronium and atracurium) was investigated in 113 patients during general anaesthesia. Neuromuscular function was monitored by recording the mechanical twitch tension of the adductor pollicis muscle of the thumb in response to ulnar nerve stimulation with single supramaximal stimuli of 0.2 ms at 0.1 Hz. In the first group of patients a benzodiazepine (diazepam 20 mg, lorazepam 5 mg, lormetazepam 2 mg or midazolam 15 mg), was injected i.v. 15 min before a single bolus of vecuronium 45 micrograms kg-1. In the second group of patients suxamethonium 1 mg kg-1 was given for endotracheal intubation, and 30 min later the patients received atracurium 200 micrograms kg-1. Fifteen min before injection of atracurium one of the same benzodiazepines as in the first group was injected i.v. Comparisons were made with control patients receiving thiopentone. Neither benzodiazepine caused significant potentiation of neuromuscular blocking agents in comparison with control. With midazolam, however, the duration to 25% and to 75% recovery of the twitch height after vecuronium was significantly longer than with diazepam. The time to 25% recovery of the twitch height after atracurium was significantly longer in patients receiving midazolam than in those receiving diazepam. The recovery index was not influenced by the four benzodiazepines.     

Facilitation of rapid endotracheal intubations with divided doses of nondepolarizing neuromuscular blocking drugs

The authors sought to determine whether prior administration of a small, subparalyzing dose of nondepolarizing muscle relaxant would shorten the onset time of an intubating dose of muscle relaxant. Initially, in 60 anesthetized patients, twitch response of adductor pollicis to ulnar nerve stimulation was studied after a small dose of pancuronium 0.015 mg . kg-1, metocurine 0.03 mg . kg-1, or d-tubocurarine 0.04 mg . kg-1, followed 3 min later by pancuronium 0.08 mg . kg-1 or atracurium 0.4 mg . kg-1 administered iv. After 60 s, the minimum neuromuscular block, in all patients was 79.0 +/- 5.0%. A 95% depression or twitch tension occurred between 59.1 +/- 5.3 and 86.1 +/- 5.9 s. In another 60 patients, intubating conditions under similar regimen were studied, except the small dose of muscle relaxant was given immediately prior to induction of anesthesia. At the end of 60 s, good to excellent intubating conditions were present in 100% of the patients following the second dose of pancuronium and in 83% of the patients following atracurium. In 17% of the patients, after atracurium intubating conditions were fair. When nondepolarizing neuromuscular blocking drugs are administered in divided doses, neuromuscular blockade adequate for endotracheal intubation is achieved in less than 90 s. This facilitates rapid endotracheal intubation in a time comparable to using succinylcholine, without undesirable effects of the depolarizing neuromuscular blocking drugs.     

Evaluation of the timing principle with small priming doses of vecuronium]

The intubating conditions using the timing principle combined with small priming doses of vecuronium were evaluated in forty patients who underwent elective surgery. They were randomly assigned to one of two groups: 1) timing, 2) timing with priming. In timing group, vecuronium 0.15 mg.kg-1 was administered, and at the onset of clinical muscle weakness, thiopental 4-5 mg.kg-1 was given promptly. Sixty seconds after thiopental, patients were intubated. In the timing with priming group, vecuronium 0.005 mg.kg-1 was administered as priming doses. Four minutes later vecuronium 0.15 mg.kg-1 was given. The administration of thiopental and the intubation were done in the same way as in timing group. The time to onset of clinical weakness after the administration of vecuronium 0.15 mg.kg-1 was significantly shorter in the timing with priming group than that in the timing group (46.1 +/- 4.8 vs. 57.6 +/- 7.8, P < 0.01). There were no significant differences in intubating score, T1, TR, onset time, and duration between the two groups. We conclude that the timing principle combined with small priming doses of vecuronium might be safe and useful for rapid tracheal intubation.     

Rapid tracheal intubation with vecuronium: the priming principle

Following the administration of a single 0.1 mg/kg dose of vecuronium bromide, satisfactory conditions for tracheal intubation developed in 156 +/- 12 s (mean +/- SEM), and the clinical duration of the initial dose was 36 +/- 2 min. When the initial dose of vecuronium was administered in two increments, a 0.015 mg/kg "priming" dose, followed 6 min later by a 0.050 mg/kg "intubating" dose, intubation time decreased to 61 +/- 3 s and clinical duration to 21 +/- 1 min. The priming dose that had no unpleasant effect on premedicated, awake patients could be administered 3-4 min before, and the intubating dose 2 to 3 min after induction of anesthesia. With the described technique, comparable intubating conditions could be obtained just as rapidly with vecuronium as with succinylcholine chloride, without subjecting the patients to the side effects of and the complications occasionally encountered with succinylcholine. An added advantage of the use of a priming dose is that it will reveal undiagnosed, pathologic, or idiopathic increase of sensitivity to nondepolarizing muscle relaxants.     

Dose-response relationships for edrophonium and neostigmine as antagonists of atracurium and vecuronium neuromuscular blockade

To determine the potencies of edrophonium and neostigmine as antagonists of nondepolarizing neuromuscular blockade produced by atracurium and vecuronium, dose-response curves were constructed for both antagonists when given at 10% spontaneous recovery of first twitch height. Ninety ASA physical status 1 and 2 adults were given either 0.4 mg/kg atracurium or 0.08 mg/kg vecuronium during thiopental-nitrous oxide-enflurane anesthesia. Train-of-four stimulation was applied to the ulnar nerve every 12 s, and the force of contraction of the adductor pollicis muscle was recorded. When spontaneous recovery of first twitch height reached 10% of its initial control value, edrophonium (0.1, 0.2, 0.4, or 1 mg/kg) or neostigmine (0.005, 0.01, 0.02, or 0.05 mg/kg) was administered by random allocation. Neuromuscular function in another ten subjects was allowed to recover spontaneously. Assisted recovery was defined as actual recovery minus mean spontaneous recovery observed in patients who were not given antagonists. First twitch recovery was initially more rapid when vecuronium was antagonized compared with atracurium, but no difference was detected after 10 min. At 10 min the neostigmine ED80 was 0.022 +/- 0.003 (SEM) mg/kg after atracurium and 0.024 +/- 0.003 mg/kg after vecuronium. The edrophonium ED80 was 0.44 +/- 0.11 mg/kg with atracurium and 0.46 +/- 0.12 mg/kg with vecuronium, giving a neostigmine:edrophonium potency ratio of 20. Atracurium train-of-four fade could be antagonized more easily with edrophonium, whereas that of vecuronium was more easily antagonized by neostigmine. It is concluded that edrophonium and neostigmine are not equally effective against atracurium and vecuronium.     

Target controlled priming for rapid onset of intubation dose: A new approach

Purpose To determine the pattern of onset of the intubating dose when given at a monitored target priming block in either phase of the priming drug effect. Methods Sixty consenting ASA I and II patients were premedicated by intramuscular buprenorphine (5 μg·kg⁻¹) 1h before surgery. Neuromuscular junction monitoring was done by stimulating the ulnar nerve at the wrist using Myotest and recording the adductor pollicis response on Myograph-2000. After stabilization of the twitch tension at the titrated supramaximal stimulus (1 Hz), double-burst stimuli (DBS) were given to monitor the priming effect of vecuronium bromide (Vb) (0.015 mg·kg⁻¹). The DBS ratio (DBSr=D ₂/D ₁) was calculated for the DBS response, repeated at 20s. Depending on the target priming block level (DBSr 0.8, 0.6, or 0.5) and the phase of the priming block to give an intubating dose of Vb (0.8 mg·kg⁻¹) injection, all patients were randomly assigned to six study groups: group 1 (DBSr 0.8), group 3 (DBSr 0.6), and group 5 (DBSr 0.5) during the priming block progression phase (before peakD ₁ suppression), and group 2 (DBSr 0.8), group 4 (DBSr 0.6), and group 6 (DBSr 0.5) during the priming block regression phase (after peakD ₁ suppression). Anesthesia was induced by thiopental (5–7 mg·kg⁻¹) just before the intubating dose. The effect of the intubating dose on twitch stimuli (1 Hz) was monitored. Results We observed that in spite of significantly variable priming intervals for identical DBSr in two different phases, the onset time of the intubating dose to 0 response was identical in similar DBSr group patients; i.e., at 0.8 DBSr, 65.0±5.2s (group 1)vs 66.0±8.0s (group 2); at DBSr 0.6, 55.2±3.7s (group 3)vs 55.2±4.9s (group 4); and at DBSr 0.5, 43.5±4.8s (group 5)vs 43.5±4.2s (group 6). At 0 twitch response, the intubating conditions were comparable in patients of the six groups. Conclusion In conclusion, target controlled priming (DBSr) for administration of the intubating dose appears to be a useful double-vision sign to predict the onset of the effect of the intubating dose precisely.